BD competitors

Clinton Severson is a CEO at ABAXIS INC and is based in Union City, California. He studied at University of San Francisco.

Robert B. Ford is an American businessman and the thirteenth chief executive officer at Abbott Laboratories, a publicly-traded medical devices and health care company based in Abbott Park, Illinois. He received a bachelor's degree from Boston College and an MBA in business administration from the University of California, Berkeley, Haas School of Business.

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.

José E. Almeida is a Brazilian businessman. He has served as the chairman and CEO of Baxter International, Inc. since January 2016. He worked for Tyco Healthcare from 1995 to 2002. He was president of Medical Devices division from October 2006 to June 2011. He served as chairman of the board of directors of Covidien since March 2012 and as the president, chief executive officer and a director since July 2011. He became a director of EMC Corporation on Jan 12, 2015 and resigned on October 30, 2015, due to his election as chairman and CEO of Baxter. In 2015, he worked for The Carlyle Group as an Operating Executive in the Global Healthcare group.

Michel Vounatsos is Chief Executive Officer of Biogen and has served in this position and as a member of the Board of Directors since January 2017. Mr. Vounatsos joined Biogen in 2016 as Executive Vice President, Chief Commercial Officer after a 20 year career at Merck. While at Merck, he held leadership positions of increasing responsibility in Europe, China, and the U.S., driving significant and consistent growth across multiple geographies. Most recently, he served as President, Primary Care Business Line and Merck Customer Centricity leading Merck’s global primary care business unit, a role which encompassed Merck’s cardiology-metabolic, general medicine, women’s health and biosimilars groups, and developed and instituted a strategic framework for enhancing the company’s relationships with key constituents, including providers, payers and retailers and governmental bodies throughout the world. Earlier in his career, Mr. Vounatsos held management positions at Ciba-Geigy. Mr. Vounatsos received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.

Michael F. Mahoney is a Director on the board of the Boys & Girls Club of Boston. He is the Chairman and CEO of Boston Scientific.

James Zallie is executive vice president, global specialties and president, Americas. Previously, Mr. Zalled served as executive vice president, global specialties and president, North America and EMEA. Before joining Ingredion, he was president and chief executive officer of National Starch, which was acquired by Ingredion in 2010. During his 27 year tenure at National Starch, he held various positions of increasing responsibility, first in technical, then marketing and then international business management. He holds master’s degrees in food science and business administration from Rutgers University and a Bachelor of Science degree in food science from Pennsylvania State University. Mr. Zallie is a member of the board of directors for Innophos, a leading producer of specialty grade phosphate products for the food, pharmaceutical and industrial market segments.

Kevin serves as the fifth Chairman and CEO at Stryker since it was founded in 1941 by Dr. Homer Stryker, an orthopaedic surgeon. Stryker is a leading medical technology company with over 40,000 employees. Kevin was born in India, grew up in Canada, and has lived and worked in four countries and four industries. He is the current chair of AdvaMed (Med-Tech trade association) and is a member of the Business Roundtable and Business Council. He is also active with community boards.

| Architect of a six-year strategic plan on the expansion of St. Jude clinical care and research programs in Memphis and around the globe| Research focuses on understanding the genetic basis of cancer and using that information to improve the treatment of children with cancer| Launched the Pediatric Cancer Genome Project, which has sequenced the normal and cancer genomes of more than 800 young cancer patients with some of the least understood and most aggressive tumors| Appointed to the Blue Ribbon Panel to advise Vice President Joe Biden’s National Cancer Moonshot Initiative through the National Cancer Institute